Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ACOG 2021 30 April - 2 May

Reduced urinary incontinence following weight loss with semaglutide 2.4 mg in STEP 1

Christina E Boots1-2; Rachel L Batterham3-5; Dror Dicker6; Niels Zeuthen7; Luc F Van Gaal8; Donna H Ryan9;
1Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA; 2Division of Reproductive Endocrinology and Infertility, Northwestern University, Chicago, Illinois, USA; 3University College London Centre for Obesity Research, Division of Medicine, University College London, London, UK; 4National Institute of Health Research, University College London Hospital Biomedical Research Centre, London, UK; 5Centre for Weight Management and Metabolic Surgery, University College London Hospital, London, UK; 6Hasharon Hospital, Rabin Medical Centre, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; 7Novo Nordisk A/S, Søborg, Denmark; 8Department of Endocrinology, Diabetology and Metabolic Diseases, Antwerp University Hospital, Antwerp, Belgium; 9Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA;